Effects of empagliflozin on first and recurrent clinical events in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a secondary analysis of the EMPA-REG OUTCOME trial
EMPA-REG OUTCOME trial was a randomized, double-blind, non-inferiority trial of patients with type 2 diabetes and atherosclerotic cardiovascular disease done between August 2010 and April 2015. For outcomes significantly reduced, risk reductions were numerically larger for total events than for first events. Total fatal or non-fatal stroke was not significantly different between treatment groups in the pooled empag liflozin group.
